AB1 in Adult Patients with Sickle Cell Disease (SCD)

Summary

This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10mg, 12mg, 16mg, and 32mg. In each dose escalation cohort, each dose will be taken orally, once daily, for 8 weeks.

Timeline

Start

2022-12-05

Primary completion

2024-10-01

Completion

2024-10-01

Outcome

Outcome not reported

Stopped (Enrollment): “Study is terminated prior to its planned completion as anticipated by the protocol due to enrollment completion. Data clean up and analysis is being performed.”

Drugs

Indications